Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targeted Antibiotics Could Get Limited Data Approval Option From FDA

Executive Summary

Achaogen has designed a registration program with a single Phase III study for its next-generation aminoglycoside, plazomicin, to treat serious infections due to carbapenem-resistant Enterobacteriaceae, in what could be an interesting test for potential modifications to the standard approval pathway.

Advertisement

Related Content

Actavis Counting On Strong Product Line Depth For Avycaz Launch
Actavis’ Avycaz Approval Shows How FDA Handles Limited-Data, Limited-Use Antibiotic
Actavis Avycaz Approval Shows How FDA Handles Limited-Data, Limited-Use Antibiotic
Skipping Past Congress: Limited Use For AZ/Actavis Antibiotic Gets FDA Review
The Regulatory Pendulum Swings In Favor Of Antibiotics, But Will Investments Follow?
Antibiotics For Drug-Resistant Infections Hope To Skip Phase III Trials
Antibiotics Stewardship Remains Open Question On Capitol Hill

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel